Icon

REVUFORJ (NDA218944)- (EQ 25MG BASE,EQ 110MG BASE,EQ 160MG BASE)

REVUMENIB CITRATE SYNDAX
EQ 25MG BASE,EQ 110MG BASE,EQ 160MG BASE
No No
Expired 2029-Nov-15
None None
None No
REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 25MG BASE ** ** - - -
EQ 110MG BASE ** ** - - -
EQ 160MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.